McGinley Kathleen F, McMahon Gregory C, Brown Gordon A
Department of Urology, Rowan University School of Osteopathic Medicine, Stratford, NJ.
Rev Urol. 2015;17(3):171-7.
On October 7, 2011, the United States Preventive Services Task Force (USPSTF) released their evidence statement and grade D recommendation against prostate-specific antigen (PSA)-based prostate cancer screening. Using a time series design, we assessed the effect of this recommendation upon evaluations for elevated PSA levels and prostate biopsies in our large urology group practice. We found that, despite a 24.1% increase in total visits, the 32 urologists in our practice completed 16.4% fewer evaluations for elevated PSA levels (317 fewer evaluations per month; P = .017) and 21.4% fewer prostate biopsies (42 fewer biopsies per month; P = .001) in the 2 years following the USPSTF grade D recommendation.
2011年10月7日,美国预防服务工作组(USPSTF)发布了其证据声明及D级建议,反对基于前列腺特异性抗原(PSA)的前列腺癌筛查。我们采用时间序列设计,评估了该建议对我们大型泌尿外科集体诊所中PSA水平升高评估及前列腺活检的影响。我们发现,尽管总就诊量增加了24.1%,但在USPSTF发布D级建议后的两年里,我们诊所的32位泌尿科医生对PSA水平升高的评估减少了16.4%(每月少317次评估;P = 0.017),前列腺活检减少了21.4%(每月少42次活检;P = 0.001)。